Daiwa Securities Group
TSHA icon

Daiwa Securities Group’s Taysha Gene Therapies TSHA Stock Holding History

Daiwa Securities Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-691
Closed -$4K – 1429
2025
Q4 		$4K Sell
691
-21,129
-97% -$103K ﹤0.01% 1259
2025
Q3 		$71K Sell
21,820
-2,021
-8% -$5.72K ﹤0.01% 1067
2025
Q2 		$55K Buy
23,841
+23,150
+3,350% +$50.3K ﹤0.01% 1059
2025
Q1 		$1K Hold
691
– – ﹤0.01% 1258
2024
Q4 		$1K Hold
691
– – ﹤0.01% 1271
2024
Q3 		$1K Hold
691
– – ﹤0.01% 1260
2024
Q2 		$2K Hold
691
– – ﹤0.01% 1268
2024
Q1 		$2K Buy
+691
New +$1.44K ﹤0.01% 1279
2022
Q4 		– Sell
-112
Closed – – 1390
2022
Q3 		$0 Hold
112
– – ﹤0.01% 1399
2022
Q2 		$0 Hold
112
– – ﹤0.01% 1426
2022
Q1 		$1K Hold
112
– – ﹤0.01% 1345
2021
Q4 		$1K Buy
+112
New +$1.69K ﹤0.01% 1364

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Daiwa Securities Group's TSHA Position: Q1 2026 in Review

Daiwa Securities Group sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 691 shares — an estimated $4K sold.

Daiwa Securities Group first reported a position in TSHA in Q4 2021 and held it in 12 quarters. The position peaked at $71K in Q3 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Daiwa Securities Group reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 691 Taysha Gene Therapies shares in Q1 2026, an estimated $4K.
  • Daiwa Securities Group first reported a position in Taysha Gene Therapies in Q4 2021 and held it in 12 quarters.
  • Daiwa Securities Group's Taysha Gene Therapies position peaked at $71K in Q3 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.